170 related articles for article (PubMed ID: 32779393)
1. A Bayesian basket trial design accounting for uncertainties of homogeneity and heterogeneity of treatment effect among subpopulations.
Asano J; Hirakawa A
Pharm Stat; 2020 Nov; 19(6):975-1000. PubMed ID: 32779393
[TBL] [Abstract][Full Text] [Related]
2. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
[TBL] [Abstract][Full Text] [Related]
3. A Bayesian basket trial design using a calibrated Bayesian hierarchical model.
Chu Y; Yuan Y
Clin Trials; 2018 Apr; 15(2):149-158. PubMed ID: 29499621
[TBL] [Abstract][Full Text] [Related]
4. Variance prior specification for a basket trial design using Bayesian hierarchical modeling.
Cunanan KM; Iasonos A; Shen R; Gönen M
Clin Trials; 2019 Apr; 16(2):142-153. PubMed ID: 30526008
[TBL] [Abstract][Full Text] [Related]
5. Bayesian adaptive basket trial design using model averaging.
Psioda MA; Xu J; Jiang Q; Ke C; Yang Z; Ibrahim JG
Biostatistics; 2021 Jan; 22(1):19-34. PubMed ID: 31107534
[TBL] [Abstract][Full Text] [Related]
6. Bayesian optimal phase II clinical trial design with time-to-event endpoint.
Zhou H; Chen C; Sun L; Yuan Y
Pharm Stat; 2020 Nov; 19(6):776-786. PubMed ID: 32524679
[TBL] [Abstract][Full Text] [Related]
7. rBMA: A robust Bayesian Model Averaging Method for phase II basket trials based on informative mixture priors.
Wang X; Wei W
Contemp Clin Trials; 2024 May; 140():107505. PubMed ID: 38521384
[TBL] [Abstract][Full Text] [Related]
8. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
Takeda K; Morita S; Taguri M
Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
[TBL] [Abstract][Full Text] [Related]
9. A comparison of Bayesian information borrowing methods in basket trials and a novel proposal of modified exchangeability-nonexchangeability method.
Daniells L; Mozgunov P; Bedding A; Jaki T
Stat Med; 2023 Oct; 42(24):4392-4417. PubMed ID: 37614070
[TBL] [Abstract][Full Text] [Related]
10. A Bayesian basket trial design that borrows information across strata based on the similarity between the posterior distributions of the response probability.
Fujikawa K; Teramukai S; Yokota I; Daimon T
Biom J; 2020 Mar; 62(2):330-338. PubMed ID: 31608505
[TBL] [Abstract][Full Text] [Related]
11. Bayesian basket trial design with exchangeability monitoring.
Hobbs BP; Landin R
Stat Med; 2018 Nov; 37(25):3557-3572. PubMed ID: 29984488
[TBL] [Abstract][Full Text] [Related]
12. Increasing the efficiency of oncology basket trials using a Bayesian approach.
Liu R; Liu Z; Ghadessi M; Vonk R
Contemp Clin Trials; 2017 Dec; 63():67-72. PubMed ID: 28629993
[TBL] [Abstract][Full Text] [Related]
13. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
Teramukai S; Daimon T; Zohar S
Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
[TBL] [Abstract][Full Text] [Related]
14. Optimal adaptive single-arm phase II trials under quantified uncertainty.
Kunzmann K; Kieser M
J Biopharm Stat; 2020; 30(1):89-103. PubMed ID: 31023135
[TBL] [Abstract][Full Text] [Related]
15. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
Dong G; Shih WJ; Moore D; Quan H; Marcella S
Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
[TBL] [Abstract][Full Text] [Related]
16. Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials.
Berry SM; Broglio KR; Groshen S; Berry DA
Clin Trials; 2013 Oct; 10(5):720-34. PubMed ID: 23983156
[TBL] [Abstract][Full Text] [Related]
17. The Bayesian basket design for genomic variant-driven phase II trials.
Simon R; Geyer S; Subramanian J; Roychowdhury S
Semin Oncol; 2016 Feb; 43(1):13-18. PubMed ID: 26970120
[TBL] [Abstract][Full Text] [Related]
18. A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints.
Chi X; Yuan Y; Yu Z; Lin R
Biom J; 2024 Mar; 66(2):e2300122. PubMed ID: 38368277
[TBL] [Abstract][Full Text] [Related]
19. Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs.
Smith CL; Thomas Z; Enas N; Thorn K; Lahn M; Benhadji K; Cleverly A
Pharm Stat; 2020 May; 19(3):276-290. PubMed ID: 31903699
[TBL] [Abstract][Full Text] [Related]
20. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
